Gonadotroph tumours with a low SF‐1 labelling index are more likely to recur and are associated with enrichment of the PI3K‐AKT pathway-Reference-Cited by-同舟云学术

Gonadotroph tumours with a low SF‐1 labelling index are more likely to recur and are associated with enrichment of the PI3K‐AKT pathway

Published:2020-12-20 Issue:3 Volume:47 Page:415-427
ISSN:0305-1846
Container-title:Neuropathology and Applied Neurobiology
language:en
Short-container-title:Neuropathology Appl Neurobio

Author:

Hickman Richard A.¹^ORCID,Bruce Jeffrey N.²,Otten Marc²,Khandji Alexander G.³,Flowers Xena E.¹,Siegelin Markus¹,Lopes Beatriz⁴,Faust Phyllis L.¹,Freda Pamela U.⁵

Affiliation:

1. Department of Pathology and Cell Biology Columbia University Medical Center New York NY USA

2. Department of Neurological Surgery Columbia University Medical Center New York NY USA

3. Department of Radiology Columbia University Medical Center New York NY USA

4. Department of Pathology University of Virginia School of Medicine Charlottesville VA USA

5. Department of Medicine Columbia University Medical Center New York NY USA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute of Neurological Disorders and Stroke

Publisher

Wiley

Subject

Physiology (medical),Neurology (clinical),Neurology,Histology,Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nan.12675

Reference51 articles.

1. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal

2. From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal

3. Invited Review: Pathology of pituitary neuroendocrine tumours: present status, modern diagnostic approach, controversies and future perspectives from a neuropathological and clinical standpoint

4. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

5. Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pituitary tumours without distinct lineage differentiation express stem cell marker SOX2;Pituitary;2024-03-14

2. Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma;Frontiers in Neuroscience;2024-01-08

3. Clinical and Molecular Characteristics of Gonadotroph Pituitary Tumors According to the WHO Classification;Endocrine Pathology;2023-12-14

4. Improvement of obesity by Liupao tea is through the IRS-1/PI3K/AKT/GLUT4 signaling pathway according to network pharmacology and experimental verification;Phytomedicine;2023-02

5. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification;Neuropathology and Applied Neurobiology;2023-01-17